Novel risk score accurately predicts death without transplant in patients awaiting heart transplantation: JAMA

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-04-16 14:15 GMT   |   Update On 2024-04-17 06:16 GMT
Advertisement

USA: A recent study has revealed that the novel US-Candidate Risk Score (US-CRS) may be useful in accurately predicting the risk of death in patients awaiting heart transplantation. The study findings were published online in the Journal of the American Medical Association (JAMA) on February 13, 2024.

In the registry-based study of 16 905 heart transplant candidates, the US-CRS based on required laboratory and clinical variables outperformed the current treatment-based categorical allocation system in identifying medically urgent candidates at the highest risk of death without transplantation.

Advertisement

In the United States, there were reportedly 4,500 heart transplantations performed in 2023, a number that has been steadily increasing for at least ten years. Despite the rising number of transplantations, donor hearts remain hard to come by, which has led the Organ Procurement and Transplantation Network (OPTN) to prioritize patients who are at high risk of death unless they receive a new heart.

The US heart allocation system prioritizes medically urgent candidates at a greater risk of dying without a transplant. The current therapy-based 6-status system is susceptible to manipulation and has limited rank-ordering ability.

Against the above background, Kevin C. Zhang, Department of Medicine, University of Chicago, Chicago, Illinois, and colleagues aimed to develop and validate a candidate risk score that incorporates current laboratory, clinical, and hemodynamic data.

For this purpose, they conducted a registry-based observational study of adult heart transplant candidates (aged ≥18 years) from the US heart allocation system listed between 2019 and 2022, split by centre into training (70%) and test (30%) datasets.

A US candidate risk score model was developed by adding a predefined set of predictors to the current French Candidate Risk Score (French-CRS) model. The researchers performed sensitivity analyses, which included percutaneous ventricular assist devices (VAD) and intra-aortic balloon pumps (IABP) in the definition of short-term mechanical circulatory support (MCS) for the US-CRS.

The time-dependent area under the receiver operating characteristic curve (AUC) was used to evaluate the performance of the US-CRS model, French-CRS model, and 6-status model in the test dataset for death without transplant within 6 weeks and overall survival concordance (c-index) with integrated AUC.

The researchers reported the following findings:

  • 16 905 adult heart transplant candidates were listed (mean age, 53 years; 73% male; 58% White); 4.7% of patients died without a transplant.
  • The final US-CRS contained time-varying short-term MCS (ventricular assist–extracorporeal membrane oxygenation or temporary surgical VAD), the log of bilirubin, estimated glomerular filtration rate, the log of B-type natriuretic peptide, albumin, sodium, and durable left ventricular assist device.
  • In the test dataset, the AUC for death within 6 weeks of listing for the US-CRS model was 0.79, for the French-CRS model was 0.72, and 6-status model was 0.68.
  • The overall c-index for the US-CRS model was 0.76, the French-CRS model was 0.69, and the 6-status model was 0.67.
  • Classifying IABP and percutaneous VAD as short-term MCS reduced the effect size by 54%.

"The findings showed that a continuous multivariable allocation score outperformed the 6-status system in rank ordering heart transplant candidates by medical urgency and may be useful for the medical urgency component of heart allocation," the researchers concluded.

Reference:

Zhang KC, Narang N, Jasseron C, et al. Development and Validation of a Risk Score Predicting Death Without Transplant in Adult Heart Transplant Candidates. JAMA. 2024;331(6):500–509. doi:10.1001/jama.2023.27029


Tags:    
Article Source : Journal of the American Medical Association (JAMA)

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News